PEDIATRICS Vol. 75 No. 2 February 1985, pp. 352-355
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reeves, J. D.
Right arrow Articles by Yip, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reeves, J. D.
Right arrow Articles by Yip, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Lack of Adverse Side Effects of Oral Ferrous Sulfate Therapy in 1-Year-Old Infants

Jerry D. Reeves USAF, MC1 and Ray Yip MD1

1 From the Departments of Pediatrics, David Grant USAF Medical Center, Travis Air Force Base, California, and University of California Medical Center, San Francisco

An evaluation was made of 278 healthy-appearing 1-year-old infants who were tested for iron deficiency to determine the relative frequency of adverse side effects attributable to oral iron treatment. After obtaining parental informed consent, laboratory tests of iron status were performed on venous blood and infants with hemoglobin level greater than 10.5 g/dL were randomly chosen to receive 1.2 mL of ferrous sulfate (FeSO4) drops (about 3 mg of iron per kilogram per day) or equal volume of placebo for 3 months. After 3 months of treatment, infants were to return to the clinic for repeat blood testing, compliance estimation, and evaluation for possible adverse side effects. There was no significant difference (P > .50) in the frequency of vomiting, diarrhea, or fussiness in iron-treated infants (6%) compared with placebo-treated infants (9%). Constipation was slightly more frequently reported (P = .03) in placebotreated infants (9%) than in iron-treated infants (1%). Compliance with therapy was confirmed in 179 completely evaluated infants by the lack of remaining medication at 3 months, the higher incidence (P < .0001) of dark stools reported among iron-treated infants, and the changes in laboratory tests of iron status. No parents reported dark stools as an adverse effect of therapy. It is concluded that once daily, moderate-dose FeSO4 therapy given to fasting 1-year-old infants results in no more gastrointestinal side effects than placebo therapy.

Key Words: iron therapy • iron deficiency

Submitted on January 23, 1984
Accepted on June 14, 1984


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
M. R. Corkins
Are Diet and Constipation Related in Children?
Nutr Clin Pract, October 1, 2005; 20(5): 536 - 539.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. R. Franz, W. A. Mihatsch, S. Sander, M. Kron, and F. Pohlandt
Prospective Randomized Trial of Early Versus Late Enteral Iron Supplementation in Infants With a Birth Weight of Less Than 1301 Grams
Pediatrics, October 1, 2000; 106(4): 700 - 706.
[Abstract] [Full Text]

Home page
 PediatricsHome page
Committee on Nutrition
Iron Fortification of Infant Formulas
Pediatrics, July 1, 1999; 104(1): 119 - 123.
[Abstract] [Full Text]